Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.

about

Identification of long non-coding RNA competing interactions and biological pathways associated with prognosis in pediatric and adolescent cytogenetically normal acute myeloid leukemia

P2860

Q58699070-CEA595A9-FC8F-4831-8A87-B26E29890703

P2860

Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.

Item

http://www.wikidata.org/entity/Q48250287

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Risk-stratified therapy for ch ...... s from the JPLSG AML-05 study.

@en

Risk-stratified therapy for ch ...... s from the JPLSG AML-05 study.

@nl

type

Item

label

Risk-stratified therapy for ch ...... s from the JPLSG AML-05 study.

@en

Risk-stratified therapy for ch ...... s from the JPLSG AML-05 study.

@nl

prefLabel

Risk-stratified therapy for ch ...... s from the JPLSG AML-05 study.

@en

Risk-stratified therapy for ch ...... s from the JPLSG AML-05 study.

@nl

P1476

Risk-stratified therapy for ch ...... ts from the JPLSG AML-05 study

@en

P2093

Akiko Moriya Saito

http://www.w3.org/2001/XMLSchema#string

Akio Tawa

http://www.w3.org/2001/XMLSchema#string

Akitoshi Kinoshita

http://www.w3.org/2001/XMLSchema#string

Daisuke Tomizawa

http://www.w3.org/2001/XMLSchema#string

Hideki Nakayama

http://www.w3.org/2001/XMLSchema#string

Hiroaki Goto

http://www.w3.org/2001/XMLSchema#string

Hiroshi Moritake

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Takahashi

http://www.w3.org/2001/XMLSchema#string

Katsuyoshi Koh

http://www.w3.org/2001/XMLSchema#string

Keizo Horibe

http://www.w3.org/2001/XMLSchema#string

P2860

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia.

Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia.

TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutations.

Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia.

NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report.

Clinical implications of FLT3 mutations in pediatric AML.

FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.

Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation.

FLT3 Inhibitors in Acute Myeloid Leukemia: Current Status and Future Directions.

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.

P2888

s12185-017-2395-x

P304

586-595

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12185-017-2395-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

Akira Shimada

P577

2018-01-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29330746

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.

about

P2860

P2860

Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921